Progress in this direction has been obtained with the demonstration in phase 2 clinical trials that the administration of an anti-sporozoite vaccine based on the parasite CS protein fused with the hepatitis B antigen (referred as RTS,S) in combination with the adjuvants AS01 and AS02 generates in children and infants around 50% clinical efficacy against malaria [2], [3], [4], [5]. The gene discussed is CS; the disease is malaria.